Literature DB >> 18293819

What is optimal flow and how to validate this.

Filip De Somer1.   

Abstract

Since the introduction of cardiopulmonary bypass, clinicians have tried to define the optimal blood flow for a given patient. The difficulty in determining a correct blood flow lies in the fact that cardiac surgery is done in a very inhomogeneous population, from neonates to the octogenarian, and often under non-physiologic conditions (hypothermia, hemodilution, low flow, etc.). Although clinicians acknowledge that maintaining a minimum oxygen delivery is more meaningful than using a fixed flow rate based on the metabolic needs of awake resting volunteers, the latter is most used in clinical practice. This is explained by the fact that no values are available on critical oxygen delivery for adequate tissue oxygenation under a given clinical condition. This was an overview of the relevant literature. In most centers, perfusionists use in-line monitoring, such as venous saturation or venous blood gases, for estimation of adequacy of tissue perfusion. Unfortunately, these oxygen-derived parameters have a poor correlation with anaerobic energy supply. Measurement of intermittent whole blood lactate concentration is used to compensate for this poor relationship, but as it monitors the concentration at given time points, it precludes optimally timely intervention by the perfusionist. The physiologic buffering by bicarbonate of the acid generated by converting pyruvate into lactate will produce carbon dioxide. As a consequence, carbon dioxide-derived parameters do have a good correlation with inadequate tissue perfusion. In-line monitoring of carbon dioxide production gives real-time information on tissue perfusion. Use of a standard reference flow for each patient is a poor option, because it does not reflect the metabolic need of the patient. Oxygen-derived parameters, such as venous saturation or partial venous oxygen tension, are poor predictors of anaerobic metabolism. A combination of intermittent whole blood lactate measurement with carbon dioxide-derived parameters predicts anaerobic energy production and allows proactive intervention by the perfusionist.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18293819      PMCID: PMC4680698     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  18 in total

1.  Acute renal injury and lowest hematocrit during cardiopulmonary bypass: not only a matter of cellular hypoxemia.

Authors:  Marco Ranucci; Lorenzo Menicanti; Alessandro Frigiola
Journal:  Ann Thorac Surg       Date:  2004-11       Impact factor: 4.330

2.  The independent effects of cardiopulmonary bypass hemodilutional anemia and transfusions on CABG outcomes.

Authors:  Robert H Habib; Anoar Zacharias; Thomas A Schwann; Christopher J Riordan
Journal:  Eur J Cardiothorac Surg       Date:  2005-09       Impact factor: 4.191

3.  Assessment of the relationship between cerebral and splanchnic oxygen saturations measured by near-infrared spectroscopy and direct measurements of systemic haemodynamic variables and oxygen transport after the Norwood procedure.

Authors:  J Li; G S Van Arsdell; G Zhang; S Cai; T Humpl; C A Caldarone; H Holtby; A N Redington
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

4.  Oxygen delivery during cardiopulmonary bypass and acute renal failure after coronary operations.

Authors:  Marco Ranucci; Federica Romitti; Giuseppe Isgrò; Mauro Cotza; Simonetta Brozzi; Alessandra Boncilli; Antonio Ditta
Journal:  Ann Thorac Surg       Date:  2005-12       Impact factor: 4.330

5.  Outcome with high blood lactate levels during cardiopulmonary bypass in adult cardiac operation.

Authors:  P Demers; S Elkouri; R Martineau; A Couturier; R Cartier
Journal:  Ann Thorac Surg       Date:  2000-12       Impact factor: 4.330

6.  Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery.

Authors:  Keyvan Karkouti; George Djaiani; Michael A Borger; William S Beattie; Ludwik Fedorko; Duminda Wijeysundera; Joan Ivanov; Jacek Karski
Journal:  Ann Thorac Surg       Date:  2005-10       Impact factor: 4.330

7.  Monitoring brain oxygen saturation during coronary bypass surgery: a randomized, prospective study.

Authors:  John M Murkin; Sandra J Adams; Richard J Novick; Mackenzie Quantz; Daniel Bainbridge; Ivan Iglesias; Andrew Cleland; Betsy Schaefer; Beverly Irwin; Stephanie Fox
Journal:  Anesth Analg       Date:  2007-01       Impact factor: 5.108

8.  Serum lactate as a predictor of mortality after paediatric cardiac surgery.

Authors:  M Hatherill; T Sajjanhar; S M Tibby; M P Champion; D Anderson; M J Marsh; I A Murdoch
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

9.  Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery.

Authors:  K Karkouti; W S Beattie; D N Wijeysundera; V Rao; C Chan; K M Dattilo; G Djaiani; J Ivanov; J Karski; T E David
Journal:  J Thorac Cardiovasc Surg       Date:  2005-02       Impact factor: 5.209

10.  Early lactate clearance is associated with improved outcome in severe sepsis and septic shock.

Authors:  H Bryant Nguyen; Emanuel P Rivers; Bernhard P Knoblich; Gordon Jacobsen; Alexandria Muzzin; Julie A Ressler; Michael C Tomlanovich
Journal:  Crit Care Med       Date:  2004-08       Impact factor: 7.598

View more
  3 in total

1.  Plateauing oxygen consumption.

Authors:  Jeffrey B Riley
Journal:  J Extra Corpor Technol       Date:  2008-12

2.  [Neuromonitoring and neuroprotection in cardiac anaesthesia. Nationwide survey conducted by the Cardiac Anaesthesia Working Group of the German Society of Anaesthesiology and Intensive Care Medicine].

Authors:  G Erdös; I Tzanova; U Schirmer; J Ender
Journal:  Anaesthesist       Date:  2009-03       Impact factor: 1.041

Review 3.  [Veno-arterial extracorporeal membrane oxygenation. Indications, limitations and practical implementation].

Authors:  D Lunz; A Philipp; M Dolch; F Born; Y A Zausig
Journal:  Anaesthesist       Date:  2014-09       Impact factor: 1.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.